A Bit of Advocate in All of Us

This is a guest blog post by ovarian cancer advocate Dorinda “Dee” Sparacio.
Through the years I have worked as a chemical engineer, packaging engineer, and high school computer science and math teacher. When I was diagnosed with Ovarian Cancer in 2005, I did not realize that I would “work” as an advocate longer than I held any of those positions.

Financial Toxicity and Cancer

This post was written by Teri Pollastro.

Over the last several years we have heard about precision medicine, payment reform and patient-centered care. While I was at ASCO this year, I heard a new buzz word; financial toxicity. The phenomenon of financial toxicity has been whispered about for years.

Top Stories of 2016

Now that it's the end of the year, we're looking back at the stories and articles that made us think, inspired us, and moved us to action. From a guide to the chemo experience from a breast surgeon with cancer, to the reason why ovarian cancer is often overlooked, to a graphic novelist's memoir about life with metastatic breast cancer, we've been able to feature a wide variety of perspectives and interesting stories that resonated with you on social media.

Young Professionals Support Pink and Teal!

Jordan Donohue of CBRE, Inc., and Ally Goldman of WB Wood, hosted a kickoff event last week at Madison Square Tavern for the SHARE Pink and Teal Young Professionals Group! The group is enlisting young professionals in New York City's Design/Construction/Real Estate industries to support SHARE's work in educating corporate employees about breast and ovarian cancers.

Announcing New Online Support Offerings

SHARE is excited to announce its partnership with HealthUnlocked, the social network for health!
There are 2.8 million women with a history of breast cancer in the U.S. (including 155,000 women living with metastatic breast cancer), and approximately 195,000 with ovarian cancer in the United States alone.

Kianna: Holding on to Faith During HER2+ Breast Cancer

Kianna: Holding on to Faith During HER2+ Breast Cancer

In 2013, at the age of 35, I was diagnosed with triple-positive Stage 1 breast cancer. Only a year and a half later in 2015, I was diagnosed with HER2+ breast cancer, Stage 2B. Here I was, 37 years old, being told, “Mrs. Riley, unfortunately, your breast cancer has reoccurred in the same area.”

The Status of Liquid Biopsies in Metastatic Cancer

This article was written by Joan Mancuso.

As a woman living with metastatic breast cancer, I’ve always dreaded getting a tissue biopsy of a metastasis. Even though the biopsy yields information about the tumor’s pathology and potentially affects my treatment options, I consider it a necessary evil.

National Helpline: